Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 10/20 | 0.67 |
| ▸ | F12 | P00748 | 3/20 | 0.56 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20577551 | 0.92 | C5AR1 (0.59) | C5AR1F12 | |
| SCHEMBL20576003 | 0.90 | C5AR1 (0.60) | C5AR1F12NR1H2MAPT | |
| SCHEMBL30705775 | 0.88 | C5AR1 (0.61) | C5AR1F12NR1H2PARP1TNKS2 | |
| SCHEMBL20577526 | 0.87 | C5AR1 (0.72) | C5AR1 | |
| SCHEMBL26077543 | 0.87 | C5AR1 (0.64) | C5AR1F12NR1H2PARP1TNKS2 | |
| SCHEMBL20577339 | 0.87 | C5AR1 (0.64) | C5AR1F12NR1H2PARP1TNKS2 | |
| SCHEMBL21139178 | 0.83 | C5AR1 (0.79) | C5AR1 | |
| SCHEMBL21183650 | 0.82 | F12 (0.52) | C5AR1F12NR1H2PARP1TNKS2 | |
| SCHEMBL21074087 | 0.82 | C5AR1 (0.62) | C5AR1 | |
| SCHEMBL31345719 | 0.82 | C5AR1 (0.62) | C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2023-05-18 | — | — | US | disclosed |
| CN-110997674-B | 6-5 fused rings as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2022-12-20 | — | — | CN | disclosed |
| EP-3630775-B1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20200347049-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2020-11-05 | — | — | US | disclosed |
| CN-110997674-A | 6-5 fused rings as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-10562896-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347049-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | C5AR1 1/4885F12 27/4885NR1H2 2248/4885 |
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | C5AR1 1/4885F12 27/4885NR1H2 2248/4885 |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | C5AR1 1/4885F12 27/4885NR1H2 2248/4885 |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | C5AR1 1/4885F12 27/4885NR1H2 2248/4885 |
| US-10562896-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | C5AR1 1/4885F12 27/4885NR1H2 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.